background

Orphan Europe was founded in 1990 by Mr. William Gunnarsson with the aim to provide treatment for patients with unmet medical needs suffering from rare diseases. Orphan Europe was acquired by Recordati in December 2007. A lot has happened in 18 years; today the company provides nine orphan products to patients all over the world with the help of 130 medical, scientific and marketing specialists in over 15 countries. New subsidiaries are being created, the latest ones being set up in the Middle East region.

Orphan Europe has developed excellent relationships with clinicians, researchers, patient groups, health authorities and partnering companies. We have an unmatched understanding of the European regulatory process required to gain approval for the marketing of orphan drugs and our entire infrastructure, such as production and distribution, is adapted to the particular requirements of very small production batches.

We are also committed to the improvement of knowledge about rare diseases among health care professionals. The best example of this commitment is the support of Orphan Europe Academy that provides unique, independent, high-level education on rare diseases.